Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Apremilast on MRI Outcomes in Psoriatic Arthritis
2018-002748-10Phase 4Unknown
- Sponsor
- Amgen
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apremilast in psoriatic arthritis (PsA), sponsored by Amgen. Primary endpoint: PsAMRIS Inflammation Score (BME + synovitis + tenosynovitis). Status: unknown.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2018-002748-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002748-10.